Literature DB >> 25157895

Prognostic factors of early death in a cohort of 162 adult haemophagocytic syndrome: impact of triggering disease and early treatment with etoposide.

Marc Arca1, Laurence Fardet, Lionel Galicier, Sébastien Rivière, Christophe Marzac, Cédric Aumont, Olivier Lambotte, Paul Coppo.   

Abstract

Reactive haemophagocytic syndrome is a life-threatening disease for which factors influencing the outcome remain unclear. We sought to identify determinants of early mortality in patients with reactive haemophagocytic syndrome by conducting a non-interventional retrospective multicentre study in three tertiary care teaching hospitals over a 6-year period. The medical files of 162 patients fulfilling our diagnostic criteria of haemophagocytic syndrome were reviewed. Patients were classified according to 30-d outcome following diagnosis. Thirty-three patients (20·4%) died within 30 d. Clinical features at diagnosis associated with 30-d death in univariate analysis were older age (P = 0·004), underlying lymphoma (P = 0·04), lower platelet count (P = 0·001) and elevated aspartate aminotransferase and lactate dehydrogenase (P = 0·04 both). The use of etoposide as a first-line treatment tended to be associated with a better outcome (P = 0·079). In multivariate analyses, increasing age, decreasing platelet count, underlying lymphoma and no etoposide in the management were associated with a poorer prognosis (P = 0·03, 0·01, 0·003 and 0·04, respectively). These prognostic factors could help to identify those patients more severely affected by reactive haemophagocytic syndrome, who should benefit from aggressive supportive care, combined with specific treatment of the precipitating factor.
© 2014 John Wiley & Sons Ltd.

Entities:  

Keywords:  etoposide; haemophagocytic syndrome; human immunodeficiency virus infection; lymphoma; prognostic factor

Mesh:

Substances:

Year:  2014        PMID: 25157895     DOI: 10.1111/bjh.13102

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  52 in total

1.  Consensus recommendations for the diagnosis and management of hemophagocytic lymphohistiocytosis associated with malignancies.

Authors:  Kai Lehmberg; Kim E Nichols; Jan-Inge Henter; Michael Girschikofsky; Tatiana Greenwood; Michael Jordan; Ashish Kumar; Milen Minkov; Paul La Rosée; Sheila Weitzman
Journal:  Haematologica       Date:  2015-08       Impact factor: 9.941

Review 2.  Proliferation through activation: hemophagocytic lymphohistiocytosis in hematologic malignancy.

Authors:  Eric J Vick; Kruti Patel; Philippe Prouet; Mike G Martin
Journal:  Blood Adv       Date:  2017-05-09

3.  Elevated serum myoglobin levels at hospital admission and the risk of early death among patients with hemophagocytic lymphohistiocytosis: evidence from 155 pediatric patients.

Authors:  Xun Li; Haipeng Yan; Xinping Zhang; Jiaotian Huang; Shi-Ting Xiang; Zhenya Yao; Ping Zang; Desheng Zhu; Zhenghui Xiao; Xiulan Lu
Journal:  Ann Hematol       Date:  2020-03-27       Impact factor: 3.673

4.  Hemophagocytic Lymphohistiocytosis Masquerading as Acute Liver Failure: A Single Center Experience.

Authors:  Nitin Jagtap; Mithun Sharma; Gupta Rajesh; Padaki Nagaraja Rao; Sekaran Anuradha; Manu Tandan; Mohan Ramchandani; Duvvuru Nageshwar Reddy
Journal:  J Clin Exp Hepatol       Date:  2017-04-28

Review 5.  Haemophagocytic syndrome in intensive care: The great pretender.

Authors:  Ignacio de Asua; Esteban Ciliberti
Journal:  J Intensive Care Soc       Date:  2015-04-29

6.  Transfusion requirements and 30-day mortality predictors for adult hemophagocytic lymphohistiocytosis.

Authors:  Zaher K Otrock; Brenda J Grossman; Charles S Eby
Journal:  Int J Hematol       Date:  2018-07-24       Impact factor: 2.490

7.  H-ferritin and proinflammatory cytokines are increased in the bone marrow of patients affected by macrophage activation syndrome.

Authors:  P Ruscitti; P Cipriani; P Di Benedetto; V Liakouli; O Berardicurti; F Carubbi; F Ciccia; G Guggino; G Triolo; R Giacomelli
Journal:  Clin Exp Immunol       Date:  2017-10-20       Impact factor: 4.330

8.  [Clinical characteristics of hemophagocytic syndrome: analysis of 46 cases].

Authors:  Wei-Bin Zhuo; Ya Gao; Chun-Yan Yang; Ying Xu; Yin-Tian Zhang; Dong-Mao Zhu; Bao-Hong Ping
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-06-20

9.  Requirement for containing etoposide in the initial treatment of lymphoma associated hemophagocytic lymphohistiocytosis.

Authors:  Yue Song; Jingshi Wang; Yini Wang; Lin Wu; Zhao Wang
Journal:  Cancer Biol Ther       Date:  2021-11-01       Impact factor: 4.742

Review 10.  Challenges in the diagnosis of hemophagocytic lymphohistiocytosis: Recommendations from the North American Consortium for Histiocytosis (NACHO).

Authors:  Michael B Jordan; Carl E Allen; Jay Greenberg; Michael Henry; Michelle L Hermiston; Ashish Kumar; Melissa Hines; Olive Eckstein; Stephan Ladisch; Kim E Nichols; Carlos Rodriguez-Galindo; Birte Wistinghausen; Kenneth L McClain
Journal:  Pediatr Blood Cancer       Date:  2019-07-24       Impact factor: 3.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.